Given that patients with elevated Lp(a) remain at residual risk of ASCVD (Bittner et al., 2020), the mechanisms whereby PCSK9 inhibitors lower Lp(a) concentrations merit investigation. The gene discussed is LPA; the disease is atherosclerosis.